Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies.

mAbs - 1 Dec 2026

Johansson Maria U, Kerschenmeyer Anne, Carella Alessandra, Carnal Simon, Schmidt Yannik, de Felice Alessandra, Mahler Dana, Thomas Marc, Spiga Fabio Mario, Tietz Julia, Weinert Christopher, Hess Christian, Urech David, Warmuth Stefan

Abstract excerpt

Immunogenicity prediction is widely used in the developability assessment of antibodies, and many marketed and clinical-stage therapeutics have a predicted T-cell epitope in the second complementary-determining region of their light chain (CDR2L). To investigate such CDR2Ls in more detail, we identified an antibody with a CDR2L for which a patient had developed treatment-emergent (TE) anti-drug antibodies (ADAs)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complementarity Determining Regions
Share to Epitopes, T-Lymphocyte

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ADA gene

Share to Mutation

Share to Single-Chain Antibodies

Source

Open in PubMed Open full text

Identifiers

PMID: 41424175
DOI: 10.1080/19420862.2025.2604353
PMCID: PMC12724142

Genes

CDR2L
ADA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies.PMID 41424175Read ↗

A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeuticsSemantic proximity Read ↗

Sagacious Epitope Selection for Vaccines, and Both Antibody-Based Therapeutics and Diagnostics: Tips From Virology and Oncology<strong> </strong>Semantic proximity Read ↗

AI-Guided Precision in Antibody Humanization: Structural Modeling to Minimize Immunogenicity and Preserve EfficacySemantic proximity Read ↗

Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies.Semantic proximity Read ↗

Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profilingSemantic proximity Read ↗

Immunogenicity of Therapeutic Antibodies: Mechanisms, Prediction, and Mitigation Strategies in the Era of Personalized BiologicsSemantic proximity Read ↗

Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody librariesSemantic proximity Read ↗

Human antibody polyreactivity is governed primarily by the heavy-chain complementarity-determining regionsSemantic proximity Read ↗

Monoclonal antibodies: From magic bullet to precision weaponSemantic proximity Read ↗

Design of Antigen-Specific Antibody CDRH3 Sequences Using AI and Germline-Based TemplatesSemantic proximity Read ↗

Structure- and machine learning-guided engineering demonstrate that a non-canonical disulfide in an anti-PD-1 rabbit antibody does not impede antibody developabilitySemantic proximity Read ↗

Machine Learning-Guided Engineering of High-Affinity Cross-Reactive Antibodies with Minimal MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.